Claims for Patent: 8,591,888

Summary for Patent: 8,591,888

Title:	Cadherin-11 EC1 domain antagonists for treating inflammatory joint disorders
Abstract:	The present invention relates to Cadherin-11 antagonists and compositions comprising Cadherin-11 antagonists. The invention also relates to methods for treating inflammatory joint disorders, such as rheumaotid arthritis, in a mammalian subject by administering a therapeutically effective amount of a Cadherin-11 antagonist.
Inventor(s):	McArthur; James G. (Concord, MA)
Assignee:	Synovex Corporation (Medford, MA)
Application Number:	12/811,921
Patent Claims:	1. A method of inhibiting the development of or reducing the severity of an inflammatory joint disorder in a mammalian subject in need thereof, comprising administering to the subject a therapeutically effective amount of an isolated antibody that specifically binds an EC1 domain of a mammalian Cadherin-11 protein, wherein the antibody binds an epitope comprising SEQ ID NO:11 in the EC1 domain of the mammalian Cadherin-11 protein, thereby inhibiting the development of or reducing the severity of the inflammatory joint disorder in the subject. 2. The method of claim 1, wherein the inflammatory joint disorder is selected from the group consisting of rheumatoid arthritis, osteoarthritis, psoriatic arthritis, Reiter's syndrome and ankylosing spondylitis. 3. The method of claim 1, wherein the inflammatory joint disorder is rheumatoid arthritis. 4. The method of claim 1, wherein the mammalian subject is a human. 5. The method of claim 1, wherein the isolated antibody inhibits migration, adhesion, invasion into cartilage, or intercellular signaling of cells that express said mammalian Cadherin-11 protein in one or more joints of said subject. 6. The method of claim 1, wherein the isolated antibody inhibits induction of expression or activity of an enzyme selected from the group consisting of a collagenase, a serine protease, and a matrix metalloproteinase in cells that express said mammalian Cadherin-11 protein in one or more joints of said subject. 7. The method of claim 1, wherein the isolated antibody inhibits induction of expression or activity of a cytokine or growth factor selected from the group consisting of a IL-6, IL-8, RANKL and TRANCE in cells that express said mammalian Cadherin-11 protein in one or more joints of said subject. 8. The method of claim 1, wherein isolated antibody is administered in combination with a disease-modifying anti-rheumatic drug. 9. The method of claim 1, wherein the isolated antibody binds SEQ ID NO:3. 10. The method of claim 1, wherein the isolated antibody is administered systemically. 11. The method of claim 1, wherein the isolated antibody is administered intravenously. 12. The method of claim 1, wherein the isolated antibody is administered by direct injection into a joint. 13. The method of claim 8, wherein the disease-modifying anti-rheumatic drug is methotrexate. 14. The method of claim 1, wherein the isolated antibody is administered in combination with an anti-inflammatory agent. 15. The method of claim 14, wherein the anti-inflammatory agent is an NSAID selected from the group consisting of detoprofen, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, meclofenameate, mefenamic acid, meloxicam, nabumeone, naproxen sodium, oxaprozin, piroxicam, sulindac, tolmetin, celecoxib, rofecoxib, aspirin, choline salicylate, salsalte, and sodium and magnesium salicylate. 16. The method of claim 14, wherein the anti-inflammatory agent is a disease modifying antirheumatic drug selected from the group consisting of cyclosporine, azathioprine, methotrexate, leflunomide, cyclophosphamide, hydroxychloroquine, sulfasalazine, D-penicillamine, minocycline, and gold. 17. The method of claim 14, wherein the anti-inflammatory agent is a steroid selected from the group consisting of cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, and triamcinolone. 18. The method of claim 14, wherein the anti-inflammatory agent is a recombinant protein selected from the group consisting of etanercept, infliximab, abatabacept, tocilizumab, and rituximab. 19. The method of claim 1, wherein the isolated antibody is administered to the subject in a dose of about 0.3 mg/kg to about 30 mg/kg body weight per treatment. 20. The method of claim 1, wherein the isolated antibody inhibits cartilage erosion in one or more joints of said subject. 21. A method of inhibiting the development of or reducing the severity of rheumatoid arthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an isolated antibody that specifically binds an EC1 domain of a human Cadherin-11 protein, wherein the antibody binds an epitope comprising SEQ ID NO:11 in the EC1 domain of the mammalian Cadherin-11 protein, thereby inhibiting the development of or reducing the severity of the rheumatoid arthritis in the subject. 22. The method of claim 21, wherein the isolated antibody is a humanized antibody. 23. The method of claim 21, wherein the isolated antibody inhibits cartilage erosion in one or more joints of said subject.

Details for Patent 8,591,888

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2028-01-11
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2028-01-11
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2028-01-11
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998		2028-01-11
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998		2028-01-11
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999		2028-01-11
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004		2028-01-11